PR

ProQR Therapeutics NVNASDAQ PRQR Stock Report

Last reporting period 30 Sep, 2024

Updated 18 Nov, 2024

Last price

Market cap $B

0.137

Micro

Exchange

XNAS - Nasdaq

PRQR Stock Analysis

PR

Uncovered

ProQR Therapeutics NV is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-40/100

Low score

Market cap $B

0.137

Dividend yield

Shares outstanding

71.291 B

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 181 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

View Section: Eyestock Rating